3rd DCT, HYBRID & CENTRALISED CLINICAL TRIALS WORLD CONGRESS 2027 EUROPE
Where Innovation, Collaboration and Human‐Centred Design Meet to Transform Clinical Research
Day 2 - Friday 26th February 2027
Implementation, Technology & Real‐World Delivery
- Our Past Trials PRINCIPLE and PANORAMIC
- Our Present Trial: ECRAID-Prime (30 mins) (Logistics, Recruitment and consent, Pharmacy)
- Our Future Trial: PREPARED
Bernadette Mundy, Senior Clinical Research Nurse
Emma Harper, Project Manager
Andrew Fairbairn, Clinical Researcher (General Practitioner)
Lucy Cureton, Senior Clinical Trial Manager
Mona Koshkouei, Head of GMP Operations, Principal Pharmacist
Dr Emily Bongard, Head of Operations,
Nuffield Department of Primary Care Health Sciences, University of Oxford
- Lessons learned from real‐world decentralised and hybrid deployments across multiple therapeutic areas and geographies.
- Deviations and variability introduced by remote data sources, including device inconsistencies and patient behaviour.
- Site‐centric approaches to digital workflow integration that reduce burden and improve operational clarity.
- Strategies to ensure patient safety and data integrity in remote and hybrid trial environments.
Moderator:
Dr Viraj Rajadhyaksha, Head Global Partnerships & Global Medical Ethics, AstraZeneca
Panellists:
Karina Morley, Global Head Research Innovation & Strategic Alliances BPM, AstraZeneca
Kayuri Odedra, Associate Director, Patient Inclusion, EMEA Region, Abbvie
- How decentralisation enables faster early‐phase studies and more agile operational models for small teams.
- Digital recruitment strategies tailored to niche, rare and geographically dispersed patient populations.
- Cost‐efficiency gains achieved through remote procedures, simplified workflows and reduced site dependency.
- Partnership models that allow biotech organisations to leverage CRO and technology expertise effectively.
Confirmed Allocated – Awaiting for details
- How AI can optimise protocol feasibility, reduce patient burden and improve operational predictability.
- Emerging digital biomarkers and remote assessment technologies that expand the scope of measurable endpoints.
- Predictive recruitment and retention models that support more accurate planning and resource allocation.
- Regulatory considerations for AI‐supported decision‐making and the validation of algorithmic outputs.
CONFIRMED-ALLOCATED: Awaiting for Company profile
- Operational models that support multi‐country decentralised studies with consistent quality and oversight.
- Regulatory variability across regions and strategies for harmonising digital processes internationally.
- Technology harmonisation approaches that reduce fragmentation and improve operational efficiency.
- Lessons learned from large‐scale deployments across diverse therapeutic areas.
- How to define strategic drug development
- Unmet clinical and patients need are the starting point
- Translating and breakthrough technology into a clinical and patients value
- Evidence-driven decisions
- Focus on patients impact
Dr. Najy Alsayed, Global Therapeutic Area Head, A. Menarini Pharma
- Introducing eSource and its role in connecting routine care with clinical research.
- Advancing adoption through the i~HD eSource Scale-up Task Force.
- Applying the eSource Playbook: from site readiness to implementation and scaling.
- Learning from five oncology centres: coordinator experience and evidence to support wider adoption.
Mats Sundgren, Senior Industry Scientific Director & Co-founder, European Institute, i-HD
- Communication strategies that clearly explain digital trial expectations and reduce uncertainty.
- Support models that help patients navigate remote participation challenges with confidence.
- How co‐creation strengthens trust and improves the relevance of digital trial tools.
- Approaches to ensure equitable access to digital platforms across diverse populations.
Vesela Aleksandrova, Senior Director Clinical Operations, Shionogi Europe
- AI‐driven automation tools that reduce manual burden and streamline operational processes.
- Intelligent scheduling and remote visit optimisation features that improve trial efficiency.
- How workflow intelligence enhances predictability and reduces operational risk.
- Collaboration models that align technology innovation with sponsor and CRO needs.
Joanna Bell, Programme Lead, Sustainable Healthcare Coalition
Carly Santer, Strategic Advisor, Healthcare Decarbonisation, Sustainable Healthcare Coalition
Dr Fiona Adshead, Chair, Sustainable Healthcare Coalition
- Combining insights from AI‐driven design, digital biomarkers and remote monitoring to shape next‐generation methodologies.
- Aligning biotech agility, CRO global scaling and pharma transformation to build unified operational models.
- Strengthening patient trust through transparent communication and inclusive digital engagement practices.
- Translating unified data platforms, automation and national policy into sustainable digital ecosystems.
Moderator:
Panelists:
Co-located with Patient Centricity & Collaboration World Congress 2027 Europe.
Joint Networking & Exhibit Area.
